CO5680438A2 - Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas - Google Patents
Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonasInfo
- Publication number
- CO5680438A2 CO5680438A2 CO05004450A CO05004450A CO5680438A2 CO 5680438 A2 CO5680438 A2 CO 5680438A2 CO 05004450 A CO05004450 A CO 05004450A CO 05004450 A CO05004450 A CO 05004450A CO 5680438 A2 CO5680438 A2 CO 5680438A2
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- alkyl
- group
- aryl
- carbon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- El uso del compuesto de la fórmula I o la fórmula II, o un tautómero del mismo, en la preparación de un medicamento para el uso en la inducción de la contracepción, dicho medicamento usado en combinación con al menos un modulador del receptor de estrógeno selectivo, caracterizado porque:la fórmula I tiene la estructura: en donde:R1 y R2 son sustituyentes independientes seleccionados del grupo que consiste de H, alquilo C1 a C6, alquilo C1 a C6 sustituido, alquenilo C2 a C6, alquenilo C2 a C6 sustituido, alquinilo C2 a C6, alquinilo C2 a C6 sustituido, cicloalquilo C3 a C8, cicloalquilo C3 a C8 sustituido, arilo, arilo sustituido, anillo heterocíclico basado en carbono que tiene en su esqueleto 1 a 3 heteroátomos, anillo heterocíclico basado en carbono sustituido que tiene en su esqueleto 1 a 3 heteroátomos, CORA, y NRBCORA;ó R1 y R2 están fusionados para formar un anillo seleccionado del grupo que consiste de a), b) y c), en donde dicho anillo es opcionalmente sustituido por 1 a 3 sustituyentes seleccionados del grupo que consiste de H y alquilo C1 a C3;a) un anillo espirocíclico saturado de 3 a 8 miembros basado en carbono;b) un anillo espirocíclico de 3 a 8 miembros basado en carbono que tiene uno o más dobles enlaces carbono carbono; y c) un anillo espirocíclico de 3 a 8 miembros que tiene en su esqueleto uno a tres heteroátomos seleccionados del grupo que consiste de O, S y N;RA es seleccionado del grupo que consiste de H, alquilo C1 a C3, alquilo C1 a C3 sustituido, arilo, arilo sustituido, alcoxilo C1 a C3, alcoxilo C1 a C3 sustituido, amino, aminoalquilo C1 a C3, y aminoalquilo C1 a C3 sustituido;RB es seleccionado del grupo que consiste de H, alquilo C1 a C3, y alquilo C1 a C3 sustituido;R3 es seleccionado del grupo que consiste de H, OH, NH2, alquilo C1 a C6, alquilo C1 a C6 sustituido, alquenilo C3 a C6, alquenilo C3 a C6 sustituido, alquinilo, alquinilo sustituido, y CORC;RC es seleccionado del grupo que consiste de H, alquilo C1 a C4, alquilo C1 a C4 sustituido, arilo, arilo sustituido, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39187102P | 2002-06-25 | 2002-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5680438A2 true CO5680438A2 (es) | 2006-09-29 |
Family
ID=30000766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05004450A CO5680438A2 (es) | 2002-06-25 | 2005-01-20 | Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7192956B2 (es) |
| EP (1) | EP1515725A4 (es) |
| JP (1) | JP2005535624A (es) |
| KR (1) | KR20050013247A (es) |
| CN (1) | CN1662241A (es) |
| AR (1) | AR040333A1 (es) |
| AU (1) | AU2003247608A1 (es) |
| BR (1) | BR0312024A (es) |
| CA (1) | CA2489847A1 (es) |
| CO (1) | CO5680438A2 (es) |
| CR (1) | CR7611A (es) |
| EC (1) | ECSP055576A (es) |
| IL (1) | IL165396A0 (es) |
| MX (1) | MXPA04012421A (es) |
| NO (1) | NO20045216L (es) |
| RU (1) | RU2005101638A (es) |
| TW (1) | TW200404548A (es) |
| WO (1) | WO2004000801A2 (es) |
| ZA (1) | ZA200410411B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| BR0312054A (pt) * | 2002-06-25 | 2005-10-18 | Wyeth Corp | Uso de derivados de tio-oxindol na preparação de medicamentos úteis no tratamento de condições relacionadas com hormÈnio, e kit farmacêutico |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| MXPA06011695A (es) * | 2004-04-08 | 2006-12-14 | Wyeth Corp | Metodos para minimizar las impurezas de tioamida. |
| CN100522960C (zh) * | 2004-04-08 | 2009-08-05 | 惠氏公司 | 作为黄体酮受体调节剂的硫代酰胺衍生物 |
| CN1946716B (zh) * | 2004-04-27 | 2011-12-21 | 惠氏公司 | 含有氰基吡咯的环状氨基甲酸酯和硫代氨基甲酸酯联芳基以及其制备方法 |
| AU2005272854B2 (en) * | 2004-08-13 | 2012-04-26 | Wyeth | Tanaproget derivatives, metabolites, and uses thereof |
| US7399766B2 (en) * | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| CA2575803A1 (en) * | 2004-08-20 | 2006-03-23 | Wyeth | Progesterone receptor structure |
| AU2011226814B2 (en) * | 2005-04-28 | 2013-06-13 | Wyeth Llc | Micronized tanaproget, compositions, and methods of preparing the same |
| MX2007013470A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma purificada de tanaproget. |
| CA2603594C (en) * | 2005-04-28 | 2013-11-05 | Wyeth | Micronized tanaproget and compositions containing same |
| AU2006241113B2 (en) | 2005-04-28 | 2011-08-18 | Wyeth | Micronized tanaproget, compositions, and methods of preparing the same |
| EP1874278B1 (en) | 2005-04-28 | 2009-06-24 | Wyeth | Compositions containing micronized tanaproget |
| CN101166736B (zh) * | 2005-04-28 | 2013-02-06 | 惠氏公司 | 他那普戈特的多晶型ⅱ |
| AU2011203520B2 (en) * | 2005-04-28 | 2012-06-14 | Wyeth | Micronized tanaproget and compostions containing same |
| CA2610767C (en) | 2005-06-09 | 2014-09-23 | Wyeth | Tanaproget compositions containing ethinyl estradiol |
| AU2007338102A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Processes for the preparation of (3R, 4R) -N- (4 -chlorophenyl) -1- (2, 2-difluoroethyl) -N' - [2-fluoro-4- (2-oxo-1 (2H) -pyridinyl) phenyl] -3, 4-pyrrolidinedicarboxamide |
| AU2008341138A1 (en) | 2007-12-20 | 2009-07-02 | Teva Women's Health, Inc. | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| WO2011029782A1 (en) * | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| US8703810B2 (en) | 2010-06-10 | 2014-04-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
| US20170014174A1 (en) * | 2015-07-17 | 2017-01-19 | Candela Corporation | Cryogenic Cylinder |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
| US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
| EP0155934B1 (en) | 1983-07-29 | 1989-12-06 | Duke University | Pharmaceutical compositions for treating androgen-related disorders in humans |
| GB2310660A (en) | 1996-03-01 | 1997-09-03 | Merck & Co Inc | Benzoxazinone oxytocin receptor antagonists |
| US6653297B1 (en) * | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| US6326392B1 (en) * | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| AU755165B2 (en) | 1998-10-23 | 2002-12-05 | Aventis Pharma S.A. | Preparations for topical application of substances having antiandrogenic effect |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6258802B1 (en) * | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
| WO2001030356A1 (fr) * | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| GB0010683D0 (en) * | 2000-05-03 | 2000-06-28 | Univ Bristol | Cancer therapy |
| FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
-
2003
- 2003-06-23 JP JP2004516143A patent/JP2005535624A/ja active Pending
- 2003-06-23 US US10/601,481 patent/US7192956B2/en not_active Expired - Fee Related
- 2003-06-23 EP EP03761263A patent/EP1515725A4/en not_active Withdrawn
- 2003-06-23 RU RU2005101638/15A patent/RU2005101638A/ru not_active Application Discontinuation
- 2003-06-23 AR ARP030102237A patent/AR040333A1/es not_active Application Discontinuation
- 2003-06-23 WO PCT/US2003/019751 patent/WO2004000801A2/en not_active Application Discontinuation
- 2003-06-23 KR KR10-2004-7021183A patent/KR20050013247A/ko not_active Application Discontinuation
- 2003-06-23 TW TW092116989A patent/TW200404548A/zh unknown
- 2003-06-23 CA CA002489847A patent/CA2489847A1/en not_active Abandoned
- 2003-06-23 MX MXPA04012421A patent/MXPA04012421A/es not_active Application Discontinuation
- 2003-06-23 BR BR0312024-4A patent/BR0312024A/pt not_active IP Right Cessation
- 2003-06-23 AU AU2003247608A patent/AU2003247608A1/en not_active Abandoned
- 2003-06-23 CN CN038146819A patent/CN1662241A/zh active Pending
-
2004
- 2004-11-25 IL IL16539604A patent/IL165396A0/xx unknown
- 2004-11-29 NO NO20045216A patent/NO20045216L/no not_active Application Discontinuation
- 2004-12-08 CR CR7611A patent/CR7611A/es not_active Application Discontinuation
- 2004-12-23 ZA ZA200410411A patent/ZA200410411B/en unknown
-
2005
- 2005-01-20 CO CO05004450A patent/CO5680438A2/es not_active Application Discontinuation
- 2005-01-25 EC EC2005005576A patent/ECSP055576A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004000801A2 (en) | 2003-12-31 |
| RU2005101638A (ru) | 2006-01-20 |
| US20040006060A1 (en) | 2004-01-08 |
| JP2005535624A (ja) | 2005-11-24 |
| MXPA04012421A (es) | 2005-04-19 |
| ZA200410411B (en) | 2007-06-27 |
| AU2003247608A1 (en) | 2004-01-06 |
| BR0312024A (pt) | 2005-03-22 |
| WO2004000801A3 (en) | 2004-03-25 |
| CR7611A (es) | 2006-05-30 |
| US7192956B2 (en) | 2007-03-20 |
| AR040333A1 (es) | 2005-03-30 |
| NO20045216L (no) | 2005-01-24 |
| ECSP055576A (es) | 2005-04-18 |
| TW200404548A (en) | 2004-04-01 |
| EP1515725A2 (en) | 2005-03-23 |
| EP1515725A4 (en) | 2005-09-21 |
| KR20050013247A (ko) | 2005-02-03 |
| IL165396A0 (en) | 2006-01-15 |
| CA2489847A1 (en) | 2003-12-31 |
| CN1662241A (zh) | 2005-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5680438A2 (es) | Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas | |
| CO5680439A2 (es) | Derivados de ciclotiocarbamato como moduladores de pr y su uso para el tratamiento de desordenes de la piel | |
| UY28150A1 (es) | Agentes terapeuticos | |
| BR0112856A (pt) | Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos | |
| AR027406A1 (es) | Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias. | |
| PE20060500A1 (es) | Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes | |
| NZ511394A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| AR019626A1 (es) | Antagonistas receptores y5 de neuropeptidos. | |
| AR035548A1 (es) | Compuestos organicos | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| CO5590915A2 (es) | Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales | |
| AR091400A2 (es) | Composicion farmaceutica que comprende derivados de sulfamida, proceso para prepararla y uso de dichos compuestos para preparar medicamentos | |
| BRPI0609711B8 (pt) | uso de uma solução aquosa com potencial redutivo oxidativo (orp) | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| UY27503A1 (es) | Nuevos derivados de piperazina | |
| TW200637559A (en) | 3-propenylcefem derivative | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| BRPI0417948A (pt) | derivados de quinuclidina substituìda por bicicloheterociclo fundido | |
| PE20001543A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica | |
| AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| PA8532001A1 (es) | Bifenilcarboxamidas utiles como agentes reductores de lipidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |